<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972828</url>
  </required_header>
  <id_info>
    <org_study_id>2006.440</org_study_id>
    <nct_id>NCT01972828</nct_id>
  </id_info>
  <brief_title>Early Haemodynamic Optimization Using Preload Dependence During Septic Shock = EHOSS-1</brief_title>
  <acronym>EHOSS-1</acronym>
  <official_title>Effect of Haemodynamic Optimization Using Preload Dependence Indexes and Pulmonary Thermodilution on Cardiovascular Failure Duration During Septic Shock: a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haemodynamic optimization is of paramount importance in septic shock, but is really&#xD;
      consensual and standardized during the first 6 hours of treatment. Haemodynamic treatment&#xD;
      including fluid loading management, vasoactive treatment and oxygen transport optimization is&#xD;
      mainly based on expert recommendations or non-randomized trials. Recently, preload dependence&#xD;
      indexes such as pulse pressure variation have been shown to be more accurate to predict fluid&#xD;
      responsiveness than static indexes such as filling pressures. However, whether using preload&#xD;
      dependence indexes changes septic shock prognostic remains to date unknown. The aim of this&#xD;
      non-blinded randomized controlled trial is to assess whether haemodynamic optimization using&#xD;
      preload dependence indexes and pulmonary thermodilution 1. reduces septic shock duration&#xD;
      assessed by administration duration of vasoactive treatment (primary end point), 2. reduces&#xD;
      regional hypoperfusion assessed by arterial lactate, 3. reduces lung hydrostatic oedema&#xD;
      linked to excessive fluid loading (assessed by PaO2/FIO2 ratio and extravascular lung water).&#xD;
      4. reduces organ dysfunction (assessed by the SOFA score), ICU stay and 7 and 28 day&#xD;
      mortality Control group is managed with an algorithm using filling pressures to drive&#xD;
      haemodynamic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to septic shock resolution</measure>
    <time_frame>28 days</time_frame>
    <description>shock resolution is defined by vasopressor weaning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days with hyperlactactatemia</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days with pulmonary edema</measure>
    <time_frame>28 jours</time_frame>
    <description>assessed by transpulmonary thermodilution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>PRELOAD DEPENDENCE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN 速)</intervention_name>
    <description>in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.</description>
    <arm_group_label>PRELOAD DEPENDENCE</arm_group_label>
    <other_name>Drug : ringer lactate, 0.9% saline, VOLUVEN 速</other_name>
    <other_name>Procedure: haemodynamic algorithm (see below)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN 速)</intervention_name>
    <description>in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.</description>
    <arm_group_label>CONTROL</arm_group_label>
    <other_name>Drug : ringer lactate, 0.9% saline, VOLUVEN 速</other_name>
    <other_name>Procedure: haemodynamic algorithm (see below)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18 years&#xD;
&#xD;
          -  and fulfilment of two of four criteria for the systemic inflammatory response syndrome&#xD;
&#xD;
          -  and systolic blood pressure no higher than 90 mm Hg (after a crystalloid-fluid&#xD;
             challenge of 25 ml per kilogram of body weight over a 30-minute period)&#xD;
&#xD;
          -  and documented or suspected infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  delay between first observation of hypotension and inclusion above 12 hours&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  acute coronary syndrome&#xD;
&#xD;
          -  acute cerebral vascular event (&lt; 1 month),&#xD;
&#xD;
          -  contraindication to central venous catheterization in the superior vena cava territory&#xD;
&#xD;
          -  contraindication to femoral arterial catheterization&#xD;
&#xD;
          -  active haemorrhage&#xD;
&#xD;
          -  burn injury&#xD;
&#xD;
          -  trauma&#xD;
&#xD;
          -  requirement for immediate surgery (&lt; 6 hours)&#xD;
&#xD;
          -  acute pulmonary oedema of cardiogenic origin&#xD;
&#xD;
          -  do-not-resuscitate status, or advanced directives restricting implementation of the&#xD;
             protocol.&#xD;
&#xD;
          -  Informed consent not obtained from the patient or surrogates&#xD;
&#xD;
          -  Patient already included in another therapeutic trial&#xD;
&#xD;
          -  patient previously included in the same therapeutic trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Preload dependence</keyword>
  <keyword>Pulmonary thermodilution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

